IMPACT Therapeutics: A precision oncology biotech company focused on synthetic lethality

Overview

This report is a company research report by Goldman Sachs on IMPACT Therapeutics (7630.HK), focusing on its positioning as a precision oncology biotech company centered on synthetic lethality (SL). The report initiates coverage with a Neutral rating and a 12-month target price of HK$37.6, arguing that the company’s PARP assets, broad SL target coverage, and management team experience are key strengths, while clinical development, partner commitment, talent, and commercialization capabilities remain major risks.

Core views

The report’s core view is that synthetic lethality is expected to become a mechanism with synergistic potential in cancer treatment, and PARP has already validated the commercial and clinical value of this pathway, but the “next PARP” is still at an early stage and awaits further POC validation. IMPACT Therapeutics’ strengths lie in its de-risked senaparib, key asset IMP1734, a pipeline covering 9 key SL targets, and an experienced R&D team; the Neutral rating reflects a balance between this potential and uncertainties in early-stage clinical development, licensing, and commercialization.

Analysis framework

Goldman Sachs uses a weighted valuation method of 70% DCF valuation and 30% M&A value, with DCF valuation at about US$1.1bn and M&A value at about US$1.8bn. Key parameters include a 14% discount rate, a 3% terminal growth rate, a 50% licensing success probability for IMP9064, and M&A value estimated at 12x EV/sales. The report also incorporates Goldman Sachs’ M&A framework, GS Factor Profile, and comparisons with covered companies to assess the stock’s investment profile.

Methodology notes

• Drug mechanismSynthetic Lethality (SL)

  Simultaneous defects in two pathways lead to cell death, while a defect in only one pathway does not.

  This mechanism can be used to address undruggable targets, overcome drug resistance, and create combination potential with existing standard therapies or new treatments such as ADC/RDC; PARP is currently the most successful SL target.

• Valuation methodsDCF and M&A weighted valuation

  A 12-month target price is derived from 70% DCF value and 30% M&A value.

  The report gives a DCF valuation of about US$1.1bn and an M&A value of about US$1.8bn, using assumptions such as a 14% discount rate, 3% terminal growth rate, 50% IMP9064 licensing success probability, and 12x EV/sales.

• Goldman Sachs equity frameworkGS Factor Profile

  Evaluates a stock’s relative attributes across growth, financial returns, valuation multiples, and composite metrics.

  This framework compares the company with the market and industry peers, using Goldman Sachs analyst forecasts and standardized percentiles to describe the stock’s investment profile.

• Events and M&AGoldman Sachs M&A framework

  Assesses the likelihood of a company becoming an acquisition target through qualitative and quantitative factors.

  The report incorporates M&A value into the target price composition, reflecting the potential acquisition value arising from the company’s pipeline and industry characteristics.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• IMPACT Therapeutics (7630.HK)

  The report’s coverage target, a Hong Kong-listed biotech company.

  Strengths

  Focused on synthetic lethality precision oncology, with a PARP portfolio, broad SL target coverage, and a management team with more than 30 years of drug discovery experience.

  Weaknesses

  It still faces constraints including clinical development, partner commitment, recruitment and retention of talent, and limited commercialization, manufacturing, and sales experience.

  Comparison

  It is within Goldman Sachs’ biotech coverage universe and belongs to a comparable coverage group including 3SBio, Abbisko, Antengene, CStone, and Innovent Biologics.

  Risks

  If clinical progress of PARP1 and other SL therapies falls short of expectations, or if licensing and commercialization execution are weaker than assumed, the target price and valuation thesis may come under pressure.

• PARP portfolio

  Core DCF valuation anchor, contributing about 60% of DCF value.

  Strengths

  senaparib is described as a de-risked PARP1/2i; IMP1734 is viewed as a key driver asset with a relatively strong long-term sales assumption.

  Weaknesses

  PARP-related assets still require continued validation of clinical performance, licensing, and market ramp-up capability.

  Comparison

  PARP is currently the most successful synthetic lethality target and therefore has higher certainty in the company’s valuation.

  Risks

  Clinical results, competitive dynamics, licensing execution, or sales ramp-up falling short of expectations would weaken valuation support.

• Non-PARP synthetic lethality pipeline

  A source of medium- to long-term growth optionality and platform value.

  Strengths

  Covers 9 of 12 key SL targets and extends into novel modalities such as ADC and protein degradation.

  Weaknesses

  Beyond PARP, the “next PARP” is still at an early stage and awaits further POC validation.

  Comparison

  Compared with single-target companies, broad SL coverage increases platform optionality but also raises R&D portfolio complexity.

  Risks

  If early-stage SL targets fail to demonstrate clinical efficacy or differentiation, the platform premium may be difficult to realize.

Key data

• RatingNeutralThe report title section shows “initiate at Neutral”.
• 12-month target priceHK$37.6The report states “12m forward TP of HK$37.6”.
• Disclosed priceHK$37.00Impact Therapeutics (HK$37.00) is listed in the company-specific regulatory disclosure.
• DCF valuation weight70%The target price framework uses 70% DCF value and 30% M&A value.
• M&A value weight30%M&A value of US$1.8bn is incorporated into the weighted valuation.
• Discount rate14%The report says this is in line with small-cap biotech companies.
• Terminal growth rate3%The report says this assumption is based on the broader SL pipeline.
• IMP1734 peak sales assumption2036E global risk-adjusted peak sales of US$1.1bnThe report identifies IMP1734 as a key driver.
• senaparib peak sales assumptionChina/EU peak sales of Rmb1bn/US$195mnThe figure caption says senaparib is a de-risked PARP1/2i, providing downside protection.
• IMP9064 licensing success probability50%The report lists the PoLS of IMP9064 (ATR inhibitor) as 50%.
• SL target coverageCoverage of 9 out of 12 key SL targetsThe company has a broader SL target布局 beyond PARP.

Impact & implications

For investors, the investment case for IMPACT Therapeutics mainly depends on whether its PARP assets can deliver on the valuation anchor, whether IMP1734 can become a medium- to long-term sales driver, and whether the non-PARP SL pipeline can generate next-stage value through POC validation. The Neutral rating means Goldman Sachs believes the current share price has limited room versus the target price, and that in the short term greater attention should be paid to the delivery of clinical, licensing, and key catalyst milestones.

Risks

• Clinical development risk for PARP1 and other SL therapies.
• Partner commitment and licensing execution risk.
• Challenges in recruiting and retaining key talent.
• Limited track record in commercial manufacturing and sales.
• SL targets beyond PARP are still at an early stage and await more POC validation.
• Valuation is relatively sensitive to IMP1734 peak sales, IMP9064 licensing success probability, discount rate, and M&A assumptions.

What to watch

• Clinical progress, licensing developments, and the delivery of 2031E/2036E sales assumptions for IMP1734.
• Commercialization and peak sales trajectory of senaparib in the China and EU markets.
• Licensing success probability and external partnership progress for IMP9064 (ATR inhibitor).
• Whether non-PARP SL targets can generate clear POC data.
• The company’s R&D expansion into new modalities such as ADC, RDC, and protein degradation.
• Whether key catalysts over the next 12 months match Goldman Sachs’ target price assumptions.